Loading song details...
CARTITUDE 4 ASH 2024 Cilta Cel Vs SoC In Lenalidomide Refractory MM After 1 3 Lines Of Therapy
No description available.
MP3 Download
Video Download
Related Songs
4:06
CARTITUDE 4 ASH 2024 Cilta Cel Vs SoC In Lenalidomide Refractory MM After 1 3 Lines Of Therapy
3:06
MRD Results From Cartitude 4 Cilta Cel Vs SOC In RRMM Rakesh Popat ASH24
4:44
ASH 2025 CARTITUDE 4 Long Term PFS Outcomes With Cilta Cel For Standard Risk RRMM
3:45
Long Term PFS Updates On The CARTITUDE 4 Trial Luciano Costa MD ASH25 Myeloma CARVYKTI
4:50
Earlier Use Of Cilta Cel Is Associated With Better Immune Fitness In Multiple Myeloma CARTITUDE 4
6:18
Results From The CARTITUDE 4 Clinical Trial In Multiple Myeloma
11:43
CARTITUDE 4 Cilta Cel Vs Standard Of Care PVd Or DPd In Lenalidomide Refractory Multiple Myeloma
2:11
MRD Negativity In The CARTITUDE 4 Trial Of Cilta Cel Vs SoC R Multiple Myeloma
5:04
Long Term Follow Up Of The CARTITUDE 4 Trial Improved OS PFS With Cilta Cel In R Myeloma
8:16
Results From CARTITUDE 4 Cilta Cel For Lenalidomide Refractory Multiple Myeloma
4:37
Long Term PFS Benefit With Cilta Cel In Standard Risk Patients R Myeloma CARTITUDE 4
2:23
MRD Negativity In The CARTITUDE 4 Trial Cilta Cel Vs SoC Lenalidomide Refractory Myeloma
45:28
ASH 2025 Myeloma Special MajesTEC 3 And The Bispecific Revolution With Dr Luciano Costa
1:54
Cilta Cel Vs Standard Of Care In Functional High Risk Myeloma Findings From CARTITUDE 4
5:05
Patient Reported Outcomes In CARTITUDE 4 Cilta Cel Vs SoC R Multiple Myeloma
7:23
CARTITUDE 2 Efficacy And Safety Of Ciltacabtagene Autoleucel In Patients With Progressive MM
22:19
Multiple Myeloma ASH 2024 Highlights With Dr Robert Orlowski
2:25
CARTITUDE 5 VRd Cilta Cel Or Rd In Newly Diagnosed Multiple Myeloma
2:21
Cilta Cel Versus SoC In Functionally High Risk Myeloma With One Prior Therapy
5:49
ASH 2025 Expert Insights Early Cilta Cel Transforms Treatment For Multiple Myeloma
2:28
MAIC Of Cilta Cel Vs Ide In R Multiple Myeloma Treated With 2 4 Prior Lines Therapy
1:47
Cilta Cel In Earlier Lines Of Therapy For R Multiple Myeloma
4:17